|
|
市场分析报告
|
Hepatitis C Virus (HCV) - Market Insights, Epidemiology, and Market Forecast - 2030 ... velpatasvir), Mavyret (glecaprevir and pibrentasvir), and Vosevi (sofosbuvir/velpatasvir ... tablets), Mavyret (glecaprevir and pibrentasvir), Epclusa (sofosbuvir and ... Scenario in HCV Therapies Glecaprevir–pibrentasvir was recommended by NICE in 2018 ...
Hepatitis C Virus (HCV) Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type ... with SUS inclusions of glecaprevir/pibrentasvir for genotype 1 dominance, ... data spurring adjuvant use. Glecaprevir/Pibrentasvir: Robust at a CAGR of 2.5%–4.0%, this ... . AbbVie: Mavyret/Maviret (glecaprevir/pibrentasvir) delivered USD 1.0–1.5 billion in ...
Hepatitis C Treatment Market, 2012-2023 ... FDA approval for Mavyret (glecaprevir/pibrentasvir), for the chronic hepatitis C virus ...
NPS+ Hepatitis C Virus (HCV) Infection US [2018] ... ) Harvoni (sofosbuvir/ledipasvir; Gilead) Mavyret (pibrentasvir/glecaprevir; AbbVie) Olysio (simeprevir; Janssen ...
NPS+ Hepatitis C Virus (HCV)Infection (EU5) [2018] ... ) Harvoni (sofosbuvir/ledipasvir; Gilead) Maviret (pibrentasvir/glecaprevir; AbbVie) Olysio (simeprevir; Janssen ...
Mavyret- Drug Insight and Market Forecast – 2030 ... (100mg), an NS3/4A protease inhibitor, and pibrentasvir (40mg), an NS5A inhibitor, dosed as three ...
Innovative drugs: Mapping the pricing, reimbursement and HTA landscape ... Eluxadoline Enasidenib Etelcalcetide Eteplirsen Glecaprevir/Pibrentasvir Guselkumab Ixazomib Ixekizumab Lenvatinib Lifitegrast ...
Hepatitis C [2016]: Bulletin #3 ... its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). Merck & Co. announcing positive results from ...
|
|
|
|